Reader-supported. We may earn a commission when you use our partner links. How we’re funded

Our take

Yucca is straightforward to compare on billing and delivery. I would start with the monthly-versus-quarterly commitment decision and agree on follow-up expectations before enrolling.

$199 monthly or $475 every three monthsThree-month plan $475, advertised around $158/mo
Subcutaneous injectionFormat offered
Prescription requiredSubject to clinical evaluation

What stands out

  • Monthly and quarterly charges clearly distinguished
  • Charge follows clinician approval
  • Free expedited shipping and ongoing support advertised

What to weigh

  • Plans renew automatically until paused or canceled
  • Quarterly discount requires the larger commitment
  • Six-month weight-loss promise does not cover this offer

Two clear payment choices

Yucca’s sermorelin offer is easy to compare at the plan level: $199 billed monthly or $475 billed every three months. The quarterly option is advertised around $158 a month, but the larger charge is the number that matters when deciding how much to commit upfront.

I would start by considering flexibility. The monthly plan costs more over an equivalent period, yet it involves a smaller first purchase while the treatment plan and practical routine are being established. The quarterly choice makes more sense after those questions are settled.

The site labels the product in stock, but individual eligibility still requires clinical review. Availability describes the offer, not a guarantee that any particular person will receive a prescription. Ask whether your state and proposed formulation are supported before treating the public plan as a final quote.

An authorization hold is different from a charge

Yucca’s process page distinguishes the temporary checkout authorization from payment after prescribing. That is useful information for anyone concerned about paying before the clinician has decided whether treatment is appropriate. It also helps explain why a pending amount may appear on a card.

I would keep the confirmation showing the selected plan and the condition for charging. If no prescription is written, ask support about the hold’s release rather than assuming every pending bank entry is a completed purchase.

The distinction does not eliminate the need to understand later cancellation. Once a plan is approved and fulfillment begins, the applicable policy matters. Request the point at which an order becomes final and the process for changing or stopping future renewals before selecting a longer plan.

The subscription needs an active review point

The service describes automatic renewals at the chosen interval and reminders before renewal. I would use that reminder as a prompt to check both the next charge and the clinical plan, rather than simply let another order proceed by default.

Ask when renewal processing begins relative to shipment, how much notice a pause needs and whether clinical reassessment is required before another supply. If the clinician recommends testing or a change, find out how that affects the next scheduled order.

Yucca’s wider site also promotes a six-month weight-loss promise for qualifying GLP-1 injectable plans. That should not be carried over to sermorelin. A guarantee for another medication category does not change the refund or outcome expectations for this offer.

Convenience should support the treatment conversation

The described process uses online intake, clinician review and delivery, with ongoing support. Free expedited shipment is helpful, but pharmacy processing and carrier transit remain separate stages. Plan around the entire sequence if you have travel or a delivery limitation.

For clinical care, define the concern you want evaluated and how progress will be assessed. Yucca’s FAQ acknowledges that the evidence in healthy adults is limited and individual responses differ. That is a better starting point than treating a recovery graphic as a personal forecast.

Our results timeline review can help frame the follow-up discussion. For the injection itself, confirm the pharmacy, exact supply, storage and instructions. The preparation guide explains why those directions must match the dispensed product.

Where Yucca fits

I would consider Yucca for its clear plan totals and explanation of the payment sequence. The main choice is the degree of commitment: a smaller monthly order or a larger quarterly purchase. Neither is inherently better without a suitable clinical plan and a clear route to follow-up.

Before enrolling, I would want to know who answers clinical questions, how quickly routine messages are handled and what testing might cost if recommended. An easy initial intake is useful, but the service’s long-term value depends on what happens after the first shipment.

This assessment uses public pages checked in October 2026, not a personal treatment experience or independent pharmacy testing. Compounded sermorelin is not FDA-approved. Compare other injection programs using the same supply period and total payment, keeping unrelated weight-loss promotions out of the decision.

Common questions

How much is Yucca sermorelin?

The product page lists $199 billed monthly or $475 every three months. The displayed $158 monthly equivalent is rounded.

When is my card charged?

Yucca describes an authorization hold at checkout and a charge only after a clinician prescribes treatment. Plans then renew at the selected interval.

Does the six-month money-back promise cover sermorelin?

The process page limits that promise to qualifying GLP-1 injectable plans. It should not be applied to sermorelin.

Research behind the decision

Explore Yucca Health

See the current offer and decide whether you want to start a consultation.

Visit Yucca Health

Reader-supported. We may earn a commission when you use our partner links. How we’re funded

Sources & further reading

Sources reviewed October 2026. Provider prices and terms may change.

  1. Yucca Health website
  2. FDA: Understanding the risks of compounded drugs
  3. Endocrine Society: Hormones and Aging scientific statement